Login Register Cart 0
Generic placeholder image

CNS & Neurological Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5273
ISSN (Online): 1996-3181

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

Immunotherapeutics for AD: A Work in Progress

Author(s): Anuja Sharma, Jaspreet Singh Anand and Yatender Kumar *

Volume 21, Issue 9, 2022

Published on: 26 January, 2022

Page: [752 - 765] Pages: 14

DOI: 10.2174/1871527320666210903101522

Price: $65

Abstract

Alzheimer's Disease (AD), often called the 'Plague of the 21st Century,' is a progressive, irreversible neurodegenerative disorder that leads to the degeneration and death of neurons. Multiple factors, such as genetic defects, epigenetic regulations, environmental factors, or cerebrovascular damage, are a manifestation of the neurodegenerative process that begins to occur decades before the onset of disease. To date, no treatment or therapeutic strategy has proven to be potent in inhibiting its progress or reversing the effects of the disease. The ever-increasing numbers and lack of sufficient therapies that can control or reverse the effects of the disease have propelled research in the direction of devising efficient therapeutic strategies for AD. This review comprehensively discusses the active and passive immunotherapies against Amyloid-β and Tau protein, which remain the popular choice of targets for AD therapeutics. Some of the prospective immunotherapies against Aβ plaques have failed due to various reasons. Much of the research is focused on targeting Tau, specifically, targeting the mid-region of extracellular Tau due to their potential to prevent seeding and hence the spread of neurofibrillary tangles (NFTs). Thus, there is a need to thoroughly understand the disease onset mechanisms and discover effective therapeutic strategies.

Keywords: Alzheimer's Disease (AD), tau, immunotherapy, amyloid-β, NFTs, brain atrophy.

« Previous Next »
Graphical Abstract

[1]
Alzheimer's facts and figures report. 2015. Available from: https://www.alz.org/alzheimers-dementia/facts-figures
[2]
Dobson CM. Alzheimer’s disease: addressing a twenty-first century plague. Rend Lincei 2015; 26: 251-62.
[http://dx.doi.org/10.1007/s12210-015-0453-y]
[3]
Alzheimer's Disease Fact Sheet | National Institute on Aging 2015. Available from: https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet
[4]
Alzheimer's disease - symptoms and causes. Mayo Clinic 2015. Available from: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447#:~:text=The%20early%20signs%20of%20the,or%20slow%20progression%20of%20symptoms
[5]
What happens to the brain in Alzheimer's disease? | National institute on aging. 2015. Available from: https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet
[6]
Wong W. Economic burden of Alzheimer disease and managed care considerations. Am J Manag Care 2020; 26(8)(Suppl.): S177-83.
[PMID: 32840331]
[7]
Alzheimer's disease - diagnosis and treatment. Mayo clinic Available from: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/diagnosis-treatment/drc-20350453#:~:text=Memantine%20(Namenda)In%20June%202021%2C%20the%20Food,amyloid%20plaques%20in%20the%20brain
[8]
Hardy JA, Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science (80- ) 1992; 256: 184-5.
[9]
Panza F, Lozupone M, Logroscino G, Imbimbo BP. A critical appraisal of amyloid-β-targeting therapies for Alzheimer disease. Nat Rev Neurol 2019; 15(2): 73-88.
[http://dx.doi.org/10.1038/s41582-018-0116-6] [PMID: 30610216]
[10]
Montoliu-Gaya L, Villegas S. Immunotherapy for neurodegenerative diseases: The Alzheimer's disease paradigm. Curr Opin Chem Eng 2018; 19: 59-67.
[http://dx.doi.org/10.1016/j.coche.2017.12.006]
[11]
Panza F, Lozupone M, Seripa D, Imbimbo BP. Amyloid-β immunotherapy for Alzheimer disease: Is it now a long shot? Ann Neurol 2019; 85(3): 303-15.
[http://dx.doi.org/10.1002/ana.25410] [PMID: 30635926]
[12]
Lopez Lopez C, Tariot PN, Caputo A, et al. The Alzheimer's Prevention Initiative Generation Program: Study design of two randomized controlled trials for individuals at risk for clinical onset of Alzheimer's disease. Alzheimers Dement (N Y) 2019; 5: 216-27.
[http://dx.doi.org/10.1016/j.trci.2019.02.005] [PMID: 31211217]
[13]
Gilman S, Koller M, Black RS, et al. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005; 64(9): 1553-62.
[http://dx.doi.org/10.1212/01.WNL.0000159740.16984.3C] [PMID: 15883316]
[14]
Nicoll JA, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: A case report. Nat Med 2003; 9(4): 448-52.
[http://dx.doi.org/10.1038/nm840] [PMID: 12640446]
[15]
Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol 2012; 11(7): 597-604.
[http://dx.doi.org/10.1016/S1474-4422(12)70140-0] [PMID: 22677258]
[16]
Cognitive decline trips up API trials of BACE inhibitor | ALZFORUM 2015.
[17]
Lacosta AM, Pascual-Lucas M, Pesini P, et al. Safety, tolerability and immunogenicity of an active anti-Aβ40 vaccine (ABvac40) in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase I trial. Alzheimers Res Ther 2018; 10(1): 12.
[http://dx.doi.org/10.1186/s13195-018-0340-8] [PMID: 29378651]
[18]
Cognitive decline trips up API trials of BACE inhibitor | ALZFORUM. ClinicalTrialsgov 2015.
[19]
Wang CY, Wang PN, Chiu MJ, et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer’s disease. Alzheimers Dement (N Y) 2017; 3(2): 262-72.
[http://dx.doi.org/10.1016/j.trci.2017.03.005] [PMID: 29067332]
[20]
UB-311 vaccine safe in mild Alzheimer's patients, phase 2a trial shows.
[21]
Park HH, Lee KY, Kim S, et al. Novel vaccine peptide GV1001 effectively blocks β-amyloid toxicity by mimicking the extra-telomeric functions of human telomerase reverse transcriptase. Neurobiol Aging 2014; 35(6): 1255-74.
[http://dx.doi.org/10.1016/j.neurobiolaging.2013.12.015] [PMID: 24439482]
[22]
GemVax & KAEL received aproval for phase II Alzheimer's disease clinical trial 2016. Available from: http://www.gemvax.com/eng/cs/news/read.jsp?reqPageNo=1stype =titlesval=Alzheimerno=29
[23]
GV1001 Subcutaneous (SC) for the treatment of moderate Alzheimer's disease (AD) - full text view. Available from: ClinicalTrials. gov
[24]
Arndt JW, Qian F, Smith BA, et al. Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β. Sci Rep 2018; 8(1): 6412.
[http://dx.doi.org/10.1038/s41598-018-24501-0] [PMID: 29686315]
[25]
Sevigny J, Chiao P, Bussière T, et al. The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. Nature 2016; 537(7618): 50-6.
[http://dx.doi.org/10.1038/nature19323] [PMID: 27582220]
[26]
Biogen/Eisai halt phase 3 aducanumab trials. ALZFORUM 2015.
[27]
A study to evaluate safety and tolerability of aducanumab in participants with Alzheimer's disease who had previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205 - full text view. ClinicalTrialsgov 2015.
[28]
Nilsberth C, Westlind-Danielsson A, Eckman CB, et al. The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 2001; 4(9): 887-93.
[http://dx.doi.org/10.1038/nn0901-887] [PMID: 11528419]
[29]
Haass C, Steiner H. Protofibrils, the unifying toxic molecule of neurodegenerative disorders? Nat Neurosci 2001; 4(9): 859-60.
[http://dx.doi.org/10.1038/nn0901-859] [PMID: 11528409]
[30]
Logovinsky V, Satlin A, Lai R, et al. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody. Alzheimers Res Ther 2016; 8(1): 14.
[http://dx.doi.org/10.1186/s13195-016-0181-2] [PMID: 27048170]
[31]
BioArctic announces positive topline results of BAN2401 phase 2b at 18 months in early Alzheimer's disease. BioArctic 2015.
[32]
A study to confirm safety and efficacy of BAN2401 in participants with early Alzheimer's disease - full text view. Clinical- Trialsgov 2015.
[33]
Demattos RB, Lu J, Tang Y, et al. A plaque-specific antibody clears existing β-amyloid plaques in Alzheimer's disease mice. Neuron 2012; 76(5): 908-20.
[http://dx.doi.org/10.1016/j.neuron.2012.10.029] [PMID: 23217740]
[34]
Anti-amyloid therapies combine forces to knock out plaques | ALZFORUM. 2015.
[35]
Lilly's latest BACE setback embodies obstacles in Alzheimer's R&D | FierceBiotech 2015.
[36]
A study of donanemab (LY3002813) in participants with early Alzheimer's disease (TRAILBLAZER-ALZ 2) - full text view. ClinicalTrialsgov 2015.
[37]
Bohrmann B, Baumann K, Benz J, et al. Gantenerumab: A novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis 2012; 28(1): 49-69.
[http://dx.doi.org/10.3233/JAD-2011-110977] [PMID: 21955818]
[38]
End of the road for gantenerumab? Roche declares prodromal Alzheimer's trial futile | ALZFORUM. 2015.
[39]
High-dose gantenerumab lowers plaque load | ALZFORUM 2015.
[40]
Klein G, Delmar P, Voyle N, et al. Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: A PET substudy interim analysis. Alzheimers Res Ther 2019; 11(1): 101.
[http://dx.doi.org/10.1186/s13195-019-0559-z] [PMID: 31831056]
[41]
A study to evaluate the safety and tolerability of long-term administration of gantenerumab in participants with Alzheimer's disease (AD) - full text view. ClinicalTrialsgov 2015.
[42]
A study to evaluate the safety, tolerability, and efficacy of long-term gantenerumab administration in participants with Alzheimer's disease (AD) - full text view. ClinicalTrialsgov 2015.
[43]
Miles LA, Crespi GAN, Doughty L, Parker MW. Bapineuzumab captures the N-terminus of the Alzheimer's disease amyloid-beta peptide in a helical conformation. Sci Rep 2013; 3: 1302.
[http://dx.doi.org/10.1038/srep01302] [PMID: 23416764]
[44]
Salloway S, Sperling R, Fox NC, et al. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med 2014; 370(4): 322-33.
[http://dx.doi.org/10.1056/NEJMoa1304839] [PMID: 24450891]
[45]
Foroutan N, Hopkins RB, Tarride JE, Florez ID, Levine M. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis. Clin Invest Med 2019; 42(1): E53-65.
[http://dx.doi.org/10.25011/cim.v42i1.32393] [PMID: 30904037]
[46]
Knopman DS, Jack CR Jr, Wiste HJ, et al. Brain injury biomarkers are not dependent on β-amyloid in normal elderly. Ann Neurol 2013; 73(4): 472-80.
[http://dx.doi.org/10.1002/ana.23816] [PMID: 23424032]
[47]
Cacabelos R. How plausible is an Alzheimer's disease vaccine? Expert Opin Drug Discov 2020; 15(1): 1-6.
[http://dx.doi.org/10.1080/17460441.2019.1667329] [PMID: 31526140]
[48]
Loureiro JC, Pais MV, Stella F, et al. Passive antiamyloid immunotherapy for Alzheimer's disease. Curr Opin Psychiatry 2020; 33(3): 284-91.
[http://dx.doi.org/10.1097/YCO.0000000000000587] [PMID: 32040044]
[49]
RO7126209 | ALZFORUM. 2015.
[50]
A single ascending dose study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of intravenously administered RO7126209 in healthy participants - full text view. ClinicalTrialsgov 2015.
[51]
Kariolis MS, Wells RC, Getz JA, et al. Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys. Sci Transl Med 2020; 12(545): 12.
[http://dx.doi.org/10.1126/scitranslmed.aay1359] [PMID: 32461332]
[52]
Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B. Tau immunotherapies for Alzheimer's disease. Expert Opin Investig Drugs 2019; 28(6): 545-54.
[http://dx.doi.org/10.1080/13543784.2019.1619694] [PMID: 31094578]
[53]
Serrano-Pozo A, Frosch MP, Masliah E, Hyman BT. Neuropathological alterations in Alzheimer disease. Cold Spring Harb Perspect Med 2011; 1(1): a006189.
[http://dx.doi.org/10.1101/cshperspect.a006189] [PMID: 22229116]
[54]
Kopeikina KJ, Hyman BT, Spires-Jones TL. Soluble forms of tau are toxic in Alzheimer's disease. Transl Neurosci 2012; 3(3): 223-33.
[http://dx.doi.org/10.2478/s13380-012-0032-y] [PMID: 23029602]
[55]
Shafiei SS, Guerrero-Muñoz MJ, Castillo-Carranza DL. Tau oligomers: Cytotoxicity, propagation, and mitochondrial damage. Front Aging Neurosci 2017; 9: 83.
[http://dx.doi.org/10.3389/fnagi.2017.00083] [PMID: 28420982]
[56]
Clavaguera F, Bolmont T, Crowther RA, et al. Transmission and spreading of tauopathy in transgenic mouse brain. Nat Cell Biol 2009; 11(7): 909-13.
[http://dx.doi.org/10.1038/ncb1901] [PMID: 19503072]
[57]
Montagne A, Zhao Z, Zlokovic BV. Alzheimer's disease: A matter of blood-brain barrier dysfunction? J Exp Med 2017; 214(11): 3151-69.
[http://dx.doi.org/10.1084/jem.20171406] [PMID: 29061693]
[58]
Congdon EE, Sigurdsson EM. Tau-targeting therapies for Alzheimer disease. Nat Rev Neurol 2018; 14(7): 399-415.
[http://dx.doi.org/10.1038/s41582-018-0013-z] [PMID: 29895964]
[59]
Safety study of AADvac1, a Tau peptide-KLH-conjugate active vaccine to treat Alzheimer's disease - full text view. ClinicalTrialsgov 2015.
[60]
18-months safety follow-up study of AADvac1, an active tau vaccine for Alzheimer's disease - full text View. ClinicalTrialsgov 2015.
[61]
24 months safety and efficacy study of AADvac1 in patients with mild Alzheimer's disease - full text view. ClinicalTrialsgov 2015.
[62]
Axon presented positive phase II trial results of AADvac1 at AAT-AD/PD 2020. BioSpace 2015 2020.
[63]
Kontsekova E, Zilka N, Kovacech B, Novak P, Novak M. First-in-man tau vaccine targeting structural determinants essential for pathological tau-tau interaction reduces tau oligomerisation and neurofibrillary degeneration in an Alzheimer's disease model. Alzheimers Res Ther 2014; 6(4): 44.
[http://dx.doi.org/10.1186/alzrt278] [PMID: 25478017]
[64]
Novak P, Schmidt R, Kontsekova E, et al. Safety and immunogenicity of the tau vaccine AADvac1 in patients with Alzheimer's disease: A randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Neurol 2017; 16(2): 123-34.
[http://dx.doi.org/10.1016/S1474-4422(16)30331-3] [PMID: 27955995]
[65]
Terwel D, Lasrado R, Snauwaert J, et al. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice. J Biol Chem 2005; 280(5): 3963-73.
[http://dx.doi.org/10.1074/jbc.M409876200] [PMID: 15509565]
[66]
Hung SY, Fu WM. Drug candidates in clinical trials for Alzheimer's disease. J Biomed Sci 2017; 24(1): 47.
[http://dx.doi.org/10.1186/s12929-017-0355-7] [PMID: 28720101]
[67]
Panza F, Solfrizzi V, Seripa D, et al. Tau-based therapeutics for Alzheimer's disease: Active and passive immunotherapy. Immunotherapy 2016; 8(9): 1119-34.
[http://dx.doi.org/10.2217/imt-2016-0019] [PMID: 27485083]
[68]
ISRCTN - ISRCTN13033912: A study comparing the safety and effects of a new compound, ACI-35 with placebo in patients with mild to moderate Alzheimer's disease. 2015.
[69]
A study to evaluate the safety, tolerability and immunogenicity of tau targeted vaccines in participants with early Alzheimer's disease - full text view. ClinicalTrialsgov 2015.
[70]
Zommer N, Sergeant N, Schraen-Maschke S, Blum D, Buee L. Targeting phospho-Ser422 by active Tau immunotherapy in the THYTau22 mouse model: A suitable therapeutic approach. Curr Alzheimer Res 2012; 9(4): 397-405.
[71]
Medina M, Avila J. The role of extracellular Tau in the spreading of neurofibrillary pathology. Front Cell Neurosci 2014; 8: 113.
[http://dx.doi.org/10.3389/fncel.2014.00113] [PMID: 24795568]
[72]
Hanneke van der K, Nicolas C, Yu-Kang M, et al. Evidence for neuronal expression of functional Fc (epsilon and gamma) receptors. J Allergy Clin Immunol 2010.
[73]
McEwan WA, Falcon B, Vaysburd M, et al. Cytosolic Fc receptor TRIM21 inhibits seeded tau aggregation. Proc Natl Acad Sci USA 2017; 114(3): 574-9.
[http://dx.doi.org/10.1073/pnas.1607215114] [PMID: 28049840]
[74]
A randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjects - full text View. ClinicalTrialsgov 2015.
[75]
Phase 2 study of BIIB092 in participants with early Alzheimer's disease - full text view. ClinicalTrialsgov 2015.
[76]
Qureshi IA, Tirucherai G, Ahlijanian MK, Kolaitis G, Bechtold C, Grundman M. A randomized, single ascending dose study of intravenous BIIB092 in healthy participants. Alzheimer's Dement Transl Res Clin Interv 2018.
[77]
Bright J, Hussain S, Dang V, et al. Human secreted tau increases amyloid-beta production. Neurobiol Aging 2015; 36(2): 693-709.
[http://dx.doi.org/10.1016/j.neurobiolaging.2014.09.007] [PMID: 25442111]
[78]
A study to evaluate the efficacy and safety of ABBV-8E12 in subjects with early Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[79]
An extension study of ABBV-8E12 in early Alzheimer's disease (AD) - full text view. - ClinicalTrialsgov 2015.
[80]
Kfoury N, Holmes BB, Jiang H, Holtzman DM, Diamond MI. Trans-cellular propagation of Tau aggregation by fibrillar species. J Biol Chem 2012; 287(23): 19440-51.
[http://dx.doi.org/10.1074/jbc.M112.346072] [PMID: 22461630]
[81]
Holmes BB, Furman JL, Mahan TE, et al. Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci USA 2014; 111(41): E4376-85.
[http://dx.doi.org/10.1073/pnas.1411649111] [PMID: 25261551]
[82]
Yanamandra K, Jiang H, Mahan TE, et al. Anti-tau antibody reduces insoluble tau and decreases brain atrophy. Ann Clin Transl Neurol 2015; 2(3): 278-88.
[http://dx.doi.org/10.1002/acn3.176] [PMID: 25815354]
[83]
West T, Hu Y, Verghese PB, et al. Preclinical and clinical development of ABBV-8E12, a humanized Anti-Tau antibody, for treatment of Alzheimer’s disease and other tauopathies. J Prev Alzheimers Dis 2017; 4(4): 236-41.
[PMID: 29181488]
[84]
A study of RO6926496 in healthy volunteers - full text view - - ClinicalTrials.gov 2015.
[85]
A study of RO7105705 in healthy participants and participants with mild-to-moderate Alzheimer's disease - full text view - ClinicalTrials. gov 2015.
[86]
A study to evaluate the efficacy and safety of semorinemab in patients with prodromal to mild Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[87]
A study of semorinemab in patients with moderate Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[88]
Single-ascending-dose study of BIIB076 in healthy volunteers and participants with Alzheimer's disease - full text view. - ClinicalTrialsgov
[89]
Czerkowicz J, Chen W, Wang Q, et al. [P4-039]: PAN-TAU antibody BIIB076 exhibits promising safety and biomarker profile in cynomolgus monkey toxicity study. Alzheimer's Dement 2017.
[90]
A study of LY3303560 in healthy participants and participants with Alzheimer's disease (AD) - full text view - ClinicalTrials.gov 2015.
[91]
A study of LY3303560 in participants with mild cognitive impairment or Alzheimer's disease - full text view - ClinicalTrialsgov 2015.
[92]
A study of LY3303560 in participants with early symptomatic Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[93]
Alam R, Driver D, Wu S, et al. Preclinical characterization of an antibody [Ly3303560] targeting aggregated Tau. Alzheimers Dement 2017.
[http://dx.doi.org/10.1016/j.jalz.2017.07.227]
[94]
Vitale F, Giliberto L, Ruiz S, Steslow K, Marambaud P, d’Abramo C. Anti-Tau conformational scFv MC1 antibody efficiently reduces pathological tau species in adult JNPL3 mice. Acta Neuropathol Commun 2018; 6(1): 82.
[http://dx.doi.org/10.1186/s40478-018-0585-2] [PMID: 30134961]
[95]
A study to investigate safety and tolerability, pharmacokinetics and pharmacodynamics of JNJ-63733657 in healthy subjects and subjects with Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[96]
Plotkin SS, Cashman NR. Passive immunotherapies targeting Aβ and tau in Alzheimer's disease. Neurobiol Dis 2020; 144: 105010.
[http://dx.doi.org/10.1016/j.nbd.2020.105010] [PMID: 32682954]
[97]
A study to test the safety, pharmacokinetics, and pharmacodynamics of single ascending intravenous doses of UCB0107 in healthy male subjects - full text view. - ClinicalTrialsgov 2015.
[98]
Novak P, Kontsekova E, Zilka N, Novak M. Ten years of tau-targeted immunotherapy: The path walked and the roads ahead. Front Neurosci 2018; 12: 798.
[http://dx.doi.org/10.3389/fnins.2018.00798] [PMID: 30450030]
[99]
Study with lu AF87908 in healthy subjects and patients with Alzheimer's disease - full text view. - ClinicalTrialsgov
[100]
Lu AF87908 | ALZFORUM 2015.
[101]
Rosenqvist N, Asuni AA, Andersson CR, et al. Highly specific and selective anti-pS396-tau antibody C10.2 targets seeding-competent tau. Alzheimer's Dement. Transl Res Clin Interv 2018.
[102]
Safety and tolerability of PNT001 in healthy adults - full text view - ClinicalTrials.gov 2015.
[103]
Nakamura K, Greenwood A, Binder L, et al. Proline isomer-specific antibodies reveal the early pathogenic tau conformation in Alzheimer's disease. Cell 2012; 149(1): 232-44.
[http://dx.doi.org/10.1016/j.cell.2012.02.016] [PMID: 22464332]
[104]
Albayram O, Kondo A, Mannix R, et al. Cis P-tau is induced in clinical and preclinical brain injury and contributes to post-injury sequelae. Nat Commun 2017; 8(1): 1000.
[http://dx.doi.org/10.1038/s41467-017-01068-4] [PMID: 29042562]
[105]
Albayram O, MacIver B, Mathai J, et al. Traumatic Brain Injury-related voiding dysfunction in mice is caused by damage to rostral pathways, altering inputs to the reflex pathways. Sci Rep 2019; 9(1): 8646.
[http://dx.doi.org/10.1038/s41598-019-45234-8] [PMID: 31201348]
[106]
PNT001 | ALZFORUM. 2015.
[107]
Shukla V, Skuntz S, Pant HC. Deregulated Cdk5 activity is involved in inducing Alzheimer's disease. Arch Med Res 2012.
[http://dx.doi.org/10.1016/j.arcmed.2012.10.015]
[108]
Yarza R, Vela S, Solas M, Ramirez MJ. c-Jun N-terminal kinase (JNK) signaling as a therapeutic target for Alzheimer's disease. Front Pharmacol 2016.
[109]
Tell V, Hilgeroth A. Recent developments of protein kinase inhibitors as potential AD therapeutics. Front Cell Neurosci 2013; 7: 189.
[http://dx.doi.org/10.3389/fncel.2013.00189] [PMID: 24312003]
[110]
Corcoran NM, Martin D, Hutter-Paier B, et al. Sodium selenate specifically activates PP2A phosphatase, dephosphorylates tau and reverses memory deficits in an Alzheimer's disease model. J Clin Neurosci 2010; 17(8): 1025-33.
[http://dx.doi.org/10.1016/j.jocn.2010.04.020] [PMID: 20537899]
[111]
M CB, V L, G S, et al. A phase IIa randomized control trial of VEL015 (sodium selenate) in mild-moderate Alzheimer's disease. J Alzheimer's Dis 2016.
[112]
Safety study of a glycogen synthase kinase 3 (GSK3) inhibitor in patients with Alzheimer's disease - full text view - ClinicalTrials.- gov 2015.
[113]
Safety, tolerability, and efficacy of two different oral doses of NP031112 versus placebo in the treatment of patients with mild-to-moderate progressive supranuclear palsy - full text view. - ClinicalTrialsgov 2015.
[114]
Low-dose lithium for the treatment of behavioral symptoms in frontotemporal dementia - full text view. - ClinicalTrialsgov 2015.
[115]
Effect of lithium and divalproex in Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[116]
A pilot trial of lithium in subjects with progressive supranuclear palsy or corticobasal degeneration - full text view. - ClinicalTrialsgov 2015.
[117]
Evaluation of lithium as a glycogen-synthase-kinase-3 (GSK-3) inhibitor in mild cognitive impairment - full text view. - ClinicalTrialsgov 2015.
[118]
Lovestone S, Boada M, Dubois B, et al. A phase II trial of tideglusib in Alzheimer's disease. J Alzheimers Dis 2015; 45(1): 75-88.
[http://dx.doi.org/10.3233/JAD-141959] [PMID: 25537011]
[119]
Domínguez JM, Fuertes A, Orozco L, del Monte-Millán M, Delgado E, Medina M. Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem 2012; 287(2): 893-904.
[http://dx.doi.org/10.1074/jbc.M111.306472] [PMID: 22102280]
[120]
Nunes MA, Viel TA, Buck HS. Microdose lithium treatment stabilized cognitive impairment in patients with Alzheimer's disease. Curr Alzheimer Res 2013; 10(1): 104-7.
[PMID: 22746245]
[121]
Forlenza OV, De-Paula VJR, Diniz BSO. Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci 2014; 5(6): 443-50.
[http://dx.doi.org/10.1021/cn5000309] [PMID: 24766396]
[122]
Min SW, Cho SH, Zhou Y, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron 2010; 67(6): 953-66.
[http://dx.doi.org/10.1016/j.neuron.2010.08.044] [PMID: 20869593]
[123]
Min SW, Chen X, Tracy TE, et al. Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits. Nat Med 2015; 21(10): 1154-62.
[http://dx.doi.org/10.1038/nm.3951] [PMID: 26390242]
[124]
Sandhu P, Lee J, Ballard J, et al. P4-036: Pharmacokinetics and pharmacodynamics to support clinical studies of MK-8719: An O-glcnacase inhibitor for progressive supranuclear palsy. Alzheimers Dement 2016.
[125]
Safety study of TRx0237 in patients already taking medications for mild and moderate Alzheimer's disease - full text view - ClinicalTrials. gov 2015.
[126]
Safety and efficacy study evaluating TRx0237 in subjects with mild Alzheimer's disease - full text view - ClinicalTrials.gov 2015.
[127]
Pen-label study of leuco-methylthioninium bis(hydromethanesulfonate) (LMTM) in subjects with Alzheimer's disease or behavioral variant frontotemporal dementia (bvFTD) - full text view. - ClinicalTrialsgov 2015.
[128]
Panza F, Solfrizzi V, Seripa D, et al. Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer’s Disease. BioMed Res Int 2016; 2016: 3245935.
[http://dx.doi.org/10.1155/2016/3245935] [PMID: 27429978]
[129]
Wischik CM, Staff RT, Wischik DJ, et al. Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 2015; 44(2): 705-20.
[http://dx.doi.org/10.3233/JAD-142874] [PMID: 25550228]
[130]
Tau inhibitor fails again—subgroup analysis irks clinicians at CTAD | ALZFORUM 2015.
[131]
Curcumin in patients with mild to moderate Alzheimer's disease - full text view - ClinicalTrials.gov 2015.
[132]
A pilot study of curcumin and ginkgo for treating Alzheimer's disease - full text view - ClinicalTrials.gov 2015.
[133]
Early intervention in mild cognitive impairment (MCI) with curcumin + bioperine - full text view - ClinicalTrials.gov 2015.
[134]
18-month study of memory effects of curcumin - full text view - - ClinicalTrials.gov 2015.
[135]
Curcumin and yoga therapy for those at risk for Alzheimer's disease - full text view - ClinicalTrials.gov 2015.
[136]
Hu S, Maiti P, Ma Q, et al. Clinical development of curcumin in neurodegenerative disease. Expert Rev Neurother 2015; 15(6): 629-37.
[http://dx.doi.org/10.1586/14737175.2015.1044981] [PMID: 26035622]
[137]
Baum L, Lam CWK, Cheung SKK, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 2008; 28(1): 110-3.
[http://dx.doi.org/10.1097/jcp.0b013e318160862c] [PMID: 18204357]
[138]
Ringman JM, Frautschy SA, Teng E, et al. Oral curcumin for Alzheimer's disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimers Res Ther 2012; 4(5): 43.
[http://dx.doi.org/10.1186/alzrt146] [PMID: 23107780]
[139]
Cash AD, Aliev G, Siedlak SL, et al. Microtubule reduction in Alzheimer's disease and aging is independent of I" filament formation. Am J Pathol 2003; 162(5): 1623-7.
[http://dx.doi.org/10.1016/S0002-9440(10)64296-4] [PMID: 12707046]
[140]
Zhang F, Su B, Wang C, et al. Posttranslational modifications of α-tubulin in Alzheimer disease. Transl Neurodegener 2015; 4: 9.
[http://dx.doi.org/10.1186/s40035-015-0030-4] [PMID: 26029362]
[141]
Study to evaluate the safety, tolerability and the effect of BMS-241027 on cerebrospinal fluid biomarkers in subjects with mild Alzheimer's disease - full text view. - ClinicalTrialsgov 2015.
[142]
Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995; 55(11): 2325-33.
[PMID: 7757983]
[143]
Zhang B, Carroll J, Trojanowski JQ, et al. The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice. J Neurosci 2012; 32(11): 3601-11.
[http://dx.doi.org/10.1523/JNEUROSCI.4922-11.2012] [PMID: 22423084]
[144]
Study to evaluate the safety and efficacy of davunetide for the treatment of progressive supranuclear palsy - full text view. - ClinicalTrialsgov 2015.
[145]
Davunetide (AL-108) in predicted tauopathies - pilot study - full text view. - ClinicalTrialsgov 2015.
[146]
Safety, tolerability and efficacy study to evaluate subjects with mild cognitive impairment - full text view. - ClinicalTrialsgov 2015.
[147]
Magen I, Gozes I. Microtubule-stabilizing peptides and small molecules protecting axonal transport and brain function: focus on davunetide (NAP). Neuropeptides 2013; 47(6): 489-95.
[http://dx.doi.org/10.1016/j.npep.2013.10.011] [PMID: 24210139]
[148]
Boxer AL, Lang AE, Grossman M, et al. Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. Lancet Neurol 2014; 13(7): 676-85.
[http://dx.doi.org/10.1016/S1474-4422(14)70088-2] [PMID: 24873720]
[149]
Yu WH, Cuervo AM, Kumar A, et al. Macroautophagy-a novel β amyloid peptide-generating pathway activated in Alzheimer’s disease. J Cell Biol 2005; 171(1): 87-98.
[http://dx.doi.org/10.1083/jcb.200505082] [PMID: 16203860]
[150]
Wang Y, Mandelkow E. Degradation of tau protein by autophagy and proteasomal pathways. Biochemical Society Transactions 2012.
[http://dx.doi.org/10.1042/BST20120071]
[151]
Gong B, Radulovic M, Figueiredo-Pereira ME, Cardozo C. The ubiquitin-proteasome system: Potential therapeutic targets for Alzheimer's disease and spinal cord injury. Front Mol Neurosci 2016; 9: 4.
[http://dx.doi.org/10.3389/fnmol.2016.00004] [PMID: 26858599]
[152]
E GM, C DE, B BA. Phosphodiesterase-4 (PDE4) molecular pharmacology and Alzheimer's disease. Neurotherapeutics 2015.
[153]
BPN14770 single ascending dose study in healthy male and female subjects - full text view. - ClinicalTrialsgov
[154]
A multiple ascending dose study of BPN14770 in healthy young and elderly male or female subjects - full text view - ClinicalTrials. gov.

Rights & Permissions Print Cite
Article Metrics
42
1
© 2024 Bentham Science Publishers | Privacy Policy